DRD4; FFAR1; FFAR4; ADORA3; ADORA2A; ADORA1; HCAR2; | |
TSHR; NPSR1; CXCR1; | |
ALPL; PLA2G1B; TDP1; BLM; FAAH; RECQL; TERT; TK1; ADK; PIK3R1; GLO1; HPGD; HSD11B1; MPO; HSD17B1; AKR1B1; HSD17B10; ALOX15; ALDH1A1; HSD17B2; ALOX12; GFER; AKR1B10; NOX4; TNKS; PARP1; TNKS2; PYGL; APEX1; POLB; AOX1; CD38; | |
MGAM; ACHE; GAA; | |
PTPN1; | |
KCNH2; | |
BCL2; | |
MET; CAMK2B; NEK6; CSNK2A1; AKT1; DAPK1; FLT3; ABL1; SRC; IGF1R; PTK2; AURKB; GSK3B; CDK1; MAPK1; EGFR; PIM1; NUAK1; ALK; AXL; NEK2; KDR; PKN1; | |
CA6; CA12; CA5A; CA3; CA14; CA5B; CA1; CA9; CA13; CA7; CA4; CA2; | |
NR1I2; | |
ESRRB; ESRRA; | |
PPARA; PPARG; PPARD; | |
ESR1; ESR2; | |
KDM4E; | |
MAOA; ALOX5; PTGS1; XDH; | |
CASP7; CASP1; | |
MMP13; MMP12; MMP3; MMP2; MMP9; MMP1; | |
BACE1; | |
TLR2; | |
STAT6; HIF1A; NFKB1; TP53; | |
FUT7; | |
SLC28A2; SLC28A1; SLC28A3; SLCO1B3; SLCO1B1; | |
ABCC1; ABCG2; | |
LMNA; FABP5; FABP2; FABP4; MCL1; MAPT; FABP3; HTT; THPO; RAB9A; NPC1; APP; TTR; | |
L3MBTL1; SMN1;SMN2; |
Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
---|---|---|---|---|
Aspartic protease | BACE1 | Beta-secretase 1 | P56817 | CHEMBL4822 |
ATP-binding cassette | ABCC1 | Multidrug resistance-associated protein 1 | P33527 | CHEMBL3004 |
ATP-binding cassette | ABCG2 | ATP-binding cassette sub-family G member 2 | Q9UNQ0 | CHEMBL5393 |
Cysteine protease | CASP7 | Caspase-7 | P55210 | CHEMBL3468 |
Cysteine protease | CASP1 | Caspase-1 | P29466 | CHEMBL4801 |
Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
Cytochrome P450 family 2 | CYP2C8 | Cytochrome P450 2C8 | P10632 | CHEMBL3721 |
Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
Cytochrome P450 family 5 | TBXAS1 | Thromboxane-A synthase | P24557 | CHEMBL1835 |
Enzyme_unclassified | TNKS2 | Tankyrase-2 | Q9H2K2 | CHEMBL6154 |
Enzyme_unclassified | PYGL | Liver glycogen phosphorylase | P06737 | CHEMBL2568 |
Enzyme_unclassified | APEX1 | DNA-(apurinic or apyrimidinic site) lyase | P27695 | CHEMBL5619 |
Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
Enzyme_unclassified | AOX1 | Aldehyde oxidase | Q06278 | CHEMBL3257 |
Enzyme_unclassified | CD38 | Lymphocyte differentiation antigen CD38 | P28907 | CHEMBL4660 |
Enzyme_unclassified | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | P05186 | CHEMBL5979 |
Enzyme_unclassified | PLA2G1B | Phospholipase A2 group 1B | P04054 | CHEMBL4426 |
Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
Enzyme_unclassified | BLM | Bloom syndrome protein | P54132 | CHEMBL1293237 |
Enzyme_unclassified | FAAH | Anandamide amidohydrolase | O00519 | CHEMBL2243 |
Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
Enzyme_unclassified | TERT | Telomerase reverse transcriptase | O14746 | CHEMBL2916 |
Enzyme_unclassified | TK1 | Thymidine kinase, cytosolic | P04183 | CHEMBL2883 |
Enzyme_unclassified | ADK | Adenosine kinase | P55263 | CHEMBL3589 |
Enzyme_unclassified | PIK3R1 | PI3-kinase p85-alpha subunit | P27986 | CHEMBL2506 |
Enzyme_unclassified | GLO1 | Glyoxalase I | Q04760 | CHEMBL2424 |
Enzyme_unclassified | HPGD | 15-hydroxyprostaglandin dehydrogenase [NAD+] | P15428 | CHEMBL1293255 |
Enzyme_unclassified | HSD11B1 | 11-beta-hydroxysteroid dehydrogenase 1 | P28845 | CHEMBL4235 |
Enzyme_unclassified | MPO | Myeloperoxidase | P05164 | CHEMBL2439 |
Enzyme_unclassified | HSD17B1 | Estradiol 17-beta-dehydrogenase 1 | P14061 | CHEMBL3181 |
Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
Enzyme_unclassified | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P00352 | CHEMBL3577 |
Enzyme_unclassified | HSD17B2 | Estradiol 17-beta-dehydrogenase 2 | P37059 | CHEMBL2789 |
Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
Enzyme_unclassified | GFER | FAD-linked sulfhydryl oxidase ALR | P55789 | CHEMBL1741189 |
Enzyme_unclassified | AKR1B10 | Aldo-keto reductase family 1 member B10 | O60218 | CHEMBL5983 |
Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
Enzyme_unclassified | TNKS | Tankyrase-1 | O95271 | CHEMBL6164 |
Enzyme_unclassified | PARP1 | Poly [ADP-ribose] polymerase-1 | P09874 | CHEMBL3105 |
Hydrolase | MGAM | Maltase-glucoamylase | O43451 | CHEMBL2074 |
Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
Hydrolase | GAA | Lysosomal alpha-glucosidase | P10253 | CHEMBL2608 |
Lyase | CA6 | Carbonic anhydrase VI | P23280 | CHEMBL3025 |
Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
Lyase | CA5A | Carbonic anhydrase VA | P35218 | CHEMBL4789 |
Lyase | CA3 | Carbonic anhydrase III | P07451 | CHEMBL2885 |
Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
Lyase | CA5B | Carbonic anhydrase VB | Q9Y2D0 | CHEMBL3969 |
Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
Lyase | CA13 | Carbonic anhydrase XIII | Q8N1Q1 | CHEMBL3912 |
Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
Metallo protease | MMP13 | Matrix metalloproteinase 13 | P45452 | CHEMBL280 |
Metallo protease | MMP12 | Matrix metalloproteinase 12 | P39900 | CHEMBL4393 |
Metallo protease | MMP3 | Matrix metalloproteinase 3 | P08254 | CHEMBL283 |
Metallo protease | MMP2 | Matrix metalloproteinase-2 | P08253 | CHEMBL333 |
Metallo protease | MMP9 | Matrix metalloproteinase 9 | P14780 | CHEMBL321 |
Metallo protease | MMP1 | Matrix metalloproteinase-1 | P03956 | CHEMBL332 |
Methyl-lysine/arginine binding protein | L3MBTL1 | Lethal(3)malignant brain tumor-like protein 1 | Q9Y468 | CHEMBL1287622 |
Methyl-lysine/arginine binding protein | SMN1;SMN2 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
Miscellaneous ion channel | BCL2 | Apoptosis regulator Bcl-2 | P10415 | CHEMBL4860 |
Nuclear hormone receptor subfamily 1 group C | PPARA | Peroxisome proliferator-activated receptor alpha | Q07869 | CHEMBL239 |
Nuclear hormone receptor subfamily 1 group C | PPARG | Peroxisome proliferator-activated receptor gamma | P37231 | CHEMBL235 |
Nuclear hormone receptor subfamily 1 group C | PPARD | Peroxisome proliferator-activated receptor delta | Q03181 | CHEMBL3979 |
Nuclear hormone receptor subfamily 1 group I | NR1I2 | Pregnane X receptor | O75469 | CHEMBL3401 |
Nuclear hormone receptor subfamily 3 group A | ESR1 | Estrogen receptor alpha | P03372 | CHEMBL206 |
Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
Nuclear hormone receptor subfamily 3 group B | ESRRB | Estrogen-related receptor beta | O95718 | CHEMBL3751 |
Nuclear hormone receptor subfamily 3 group B | ESRRA | Estrogen-related receptor alpha | P11474 | CHEMBL3429 |
Oxidoreductase | XDH | Xanthine dehydrogenase | P47989 | CHEMBL1929 |
Oxidoreductase | MAOA | Monoamine oxidase A | P21397 | CHEMBL1951 |
Oxidoreductase | ALOX5 | Arachidonate 5-lipoxygenase | P09917 | CHEMBL215 |
Oxidoreductase | PTGS1 | Cyclooxygenase-1 | P23219 | CHEMBL221 |
Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
Peptide receptor (family A GPCR) | NPSR1 | Neuropeptide S receptor | Q6W5P4 | CHEMBL5162 |
Peptide receptor (family A GPCR) | CXCR1 | Interleukin-8 receptor A | P25024 | CHEMBL4029 |
Potassium channels | KCNH2 | HERG | Q12809 | CHEMBL240 |
Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
Protein Kinase | CAMK2B | CaM kinase II beta | Q13554 | CHEMBL4121 |
Protein Kinase | NEK6 | Serine/threonine-protein kinase NEK6 | Q9HC98 | CHEMBL4309 |
Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
Protein Kinase | AKT1 | Serine/threonine-protein kinase AKT | P31749 | CHEMBL4282 |
Protein Kinase | DAPK1 | Death-associated protein kinase 1 | P53355 | CHEMBL2558 |
Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
Protein Kinase | ABL1 | Tyrosine-protein kinase ABL | P00519 | CHEMBL1862 |
Protein Kinase | SRC | Tyrosine-protein kinase SRC | P12931 | CHEMBL267 |
Protein Kinase | IGF1R | Insulin-like growth factor I receptor | P08069 | CHEMBL1957 |
Protein Kinase | PTK2 | Focal adhesion kinase 1 | Q05397 | CHEMBL2695 |
Protein Kinase | AURKB | Serine/threonine-protein kinase Aurora-B | Q96GD4 | CHEMBL2185 |
Protein Kinase | GSK3B | Glycogen synthase kinase-3 beta | P49841 | CHEMBL262 |
Protein Kinase | CDK1 | Cyclin-dependent kinase 1 | P06493 | CHEMBL308 |
Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
Protein Kinase | EGFR | Epidermal growth factor receptor erbB1 | P00533 | CHEMBL203 |
Protein Kinase | PIM1 | Serine/threonine-protein kinase PIM1 | P11309 | CHEMBL2147 |
Protein Kinase | NUAK1 | NUAK family SNF1-like kinase 1 | O60285 | CHEMBL5784 |
Protein Kinase | ALK | ALK tyrosine kinase receptor | Q9UM73 | CHEMBL4247 |
Protein Kinase | AXL | Tyrosine-protein kinase receptor UFO | P30530 | CHEMBL4895 |
Protein Kinase | NEK2 | Serine/threonine-protein kinase NEK2 | P51955 | CHEMBL3835 |
Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
Protein Kinase | PKN1 | Protein kinase N1 | Q16512 | CHEMBL3384 |
Protein Phosphatase | PTPN1 | Protein-tyrosine phosphatase 1B | P18031 | CHEMBL335 |
SLC superfamily of solute carriers | SLC28A2 | Sodium/nucleoside cotransporter 2 | O43868 | CHEMBL5780 |
SLC superfamily of solute carriers | SLC28A1 | Sodium/nucleoside cotransporter 1 | O00337 | CHEMBL5551 |
SLC superfamily of solute carriers | SLC28A3 | Solute carrier family 28 member 3 | Q9HAS3 | CHEMBL5707 |
SLC superfamily of solute carriers | SLCO1B3 | Solute carrier organic anion transporter family member 1B3 | Q9NPD5 | CHEMBL1743121 |
SLC superfamily of solute carriers | SLCO1B1 | Solute carrier organic anion transporter family member 1B1 | Q9Y6L6 | CHEMBL1697668 |
Small molecule receptor (family A GPCR) | DRD4 | Dopamine D4 receptor | P21917 | CHEMBL219 |
Small molecule receptor (family A GPCR) | FFAR1 | Free fatty acid receptor 1 | O14842 | CHEMBL4422 |
Small molecule receptor (family A GPCR) | FFAR4 | G-protein coupled receptor 120 | Q5NUL3 | CHEMBL5339 |
Small molecule receptor (family A GPCR) | ADORA3 | Adenosine A3 receptor | P0DMS8 | CHEMBL256 |
Small molecule receptor (family A GPCR) | ADORA2A | Adenosine A2a receptor | P29274 | CHEMBL251 |
Small molecule receptor (family A GPCR) | ADORA1 | Adenosine A1 receptor | P30542 | CHEMBL226 |
Small molecule receptor (family A GPCR) | HCAR2 | Hydroxycarboxylic acid receptor 2 | Q8TDS4 | CHEMBL3785 |
Toll-like and Il-1 receptors | TLR2 | Toll-like receptor 2 | O60603 | CHEMBL4163 |
Transcription Factor | STAT6 | Signal transducer and activator of transcription 6 | P42226 | CHEMBL5401 |
Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
Transferase | FUT7 | Alpha-(1,3)-fucosyltransferase 7 | Q11130 | CHEMBL3596077 |
Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
Unclassified | FABP5 | Fatty acid binding protein epidermal | Q01469 | CHEMBL3674 |
Unclassified | FABP2 | Fatty acid binding protein intestinal | P12104 | CHEMBL4879 |
Unclassified | FABP4 | Fatty acid binding protein adipocyte | P15090 | CHEMBL2083 |
Unclassified | MCL1 | Induced myeloid leukemia cell differentiation protein Mcl-1 | Q07820 | CHEMBL4361 |
Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
Unclassified | FABP3 | Fatty acid binding protein muscle | P05413 | CHEMBL3344 |
Unclassified | HTT | Huntingtin | P42858 | CHEMBL5514 |
Unclassified | THPO | Thrombopoietin | P40225 | CHEMBL1293256 |
Unclassified | RAB9A | Ras-related protein Rab-9A | P51151 | CHEMBL1293294 |
Unclassified | NPC1 | Niemann-Pick C1 protein | O15118 | CHEMBL1293277 |
Unclassified | APP | Beta amyloid A4 protein | P05067 | CHEMBL2487 |
Unclassified | TTR | Transthyretin | P02766 | CHEMBL3194 |
GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|
BP | Unclassified; | GO:0032844; regulation of homeostatic process | 6.623E-12 | 1.658E-09 | ABL1, ADORA1, ADORA2A, AURKB, BCL2, CA2, CA7, CD38, EGFR, HCAR2, HIF1A, HTT, KDR, MAPK1, NEK2, NPC1, NPSR1, PARP1, PLA2G1B, SRC, TNKS, TNKS2 |
BP | Unclassified; | GO:0032846; positive regulation of homeostatic process | 1.191E-11 | 2.819E-09 | ABL1, ADORA2A, AURKB, CA2, CA7, EGFR, HCAR2, HIF1A, HTT, MAPK1, NEK2, NPC1, NPSR1, PLA2G1B, TNKS, TNKS2 |
MF | GO:0005488; binding | GO:0020037; heme binding | 1.181E-11 | 2.819E-09 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C8, CYP2C9, CYP3A4, MPO, NOX4, PTGS1, SRC, TBXAS1 |
MF | GO:0005488; binding | GO:0005506; iron ion binding | 1.426E-11 | 3.303E-09 | ALOX12, ALOX15, ALOX5, AOX1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C8, CYP2C9, CYP3A4, TBXAS1, XDH |
BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 3.036E-11 | 6.678E-09 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C8, CYP2C9 |
MF | GO:0005488; binding | GO:0019825; oxygen binding | 3.661E-11 | 7.739E-09 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C8, CYP2C9, CYP3A4, NOX4 |
BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 1.320E-10 | 2.355E-08 | CYP1A2, CYP2C19, CYP2C8, CYP2C9, CYP3A4, NR1I2 |
MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 2.880E-09 | 3.733E-07 | CYP1A2, CYP2C8, CYP2C9, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0018107; peptidyl-threonine phosphorylation | 6.128E-09 | 7.581E-07 | AKT1, BCL2, CAMK2B, CDK1, CSNK2A1, GSK3B, MAPK1, PKN1, TNKS |
BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 7.337E-09 | 8.975E-07 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C8, CYP2C9 |
MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 1.348E-08 | 1.468E-06 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C8, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0018105; peptidyl-serine phosphorylation | 4.133E-08 | 4.225E-06 | AKT1, AURKB, BCL2, CAMK2B, CDK1, GSK3B, MAPK1, NEK6, PKN1, SRC, TNKS |
BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 4.271E-08 | 4.317E-06 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
BP | Unclassified; | GO:2000021; regulation of ion homeostasis | 4.888E-08 | 4.860E-06 | ABL1, ADORA1, ADORA2A, BCL2, CA2, CA7, HTT, KDR, NPSR1, PARP1, PLA2G1B, SRC |
BP | GO:0008152; metabolic process | GO:0006691; leukotriene metabolic process | 9.367E-08 | 8.829E-06 | ABCC1, ALOX12, ALOX15, ALOX5, PLA2G1B, TLR2 |
MF | GO:0005488; binding | GO:0005524; ATP binding | 9.474E-08 | 8.883E-06 | ABCC1, ABCG2, ABL1, ADK, AKT1, ALK, AURKB, AXL, BLM, CAMK2B, CDK1, CSNK2A1, DAPK1, EGFR, FLT3, GSK3B, IGF1R, KDR, MAPK1, MET, NEK2, NEK6, NUAK1, PIM1, PKN1, PTK2, PYGL, RECQL, SRC, TK1, TP53 |
BP | GO:0065007; biological regulation | GO:1904355; positive regulation of telomere capping | 1.194E-07 | 1.083E-05 | AURKB, MAPK1, NEK2, TNKS, TNKS2 |
BP | GO:0009987; cellular process | GO:0070301; cellular response to hydrogen peroxide | 3.286E-07 | 2.660E-05 | ABL1, AKR1B1, APEX1, AXL, CDK1, CYP1B1, STAT6 |
BP | GO:0032501; multicellular organismal process | GO:0048143; astrocyte activation | 3.526E-07 | 2.844E-05 | ADORA2A, APP, EGFR, MAPT |
BP | GO:0009987; cellular process | GO:0043401; steroid hormone mediated signaling pathway | 5.344E-07 | 4.021E-05 | ESR1, ESR2, ESRRA, ESRRB, NR1I2, PPARA, PPARD, PPARG, SRC |
CC | GO:0043226; organelle | GO:0005654; nucleoplasm | 6.925E-07 | 5.146E-05 | ABL1, ADK, AKR1B1, AKT1, ALOX5, APEX1, AURKB, BCL2, BLM, CAMK2B, CASP7, CDK1, CSNK2A1, ESR1, ESR2, ESRRA, ESRRB, FABP5, GSK3B, HIF1A, HPGD, HTT, L3MBTL1, LMNA, MAPK1, MCL1, NEK2, NEK6, NFKB1, NR1I2, NUAK1, PARP1, PIM1, PKN1, POLB, PPARA, PPARD, PPARG, RECQL, SMN1, SMN2, SRC, STAT6, TERT, TNKS, TP53 |
BP | GO:0009987; cellular process | GO:0030522; intracellular receptor signaling pathway | 7.284E-07 | 5.340E-05 | ESR1, ESR2, ESRRA, ESRRB, NR1I2, PIM1, PPARA, PPARD, PPARG, SRC |
BP | GO:0009987; cellular process | GO:0071456; cellular response to hypoxia | 1.049E-06 | 7.299E-05 | AKT1, BCL2, HIF1A, LMNA, PPARD, SRC, TERT, TP53 |
BP | Unclassified; | GO:0044243; multicellular organismal catabolic process | 1.140E-06 | 7.853E-05 | MMP1, MMP12, MMP13, MMP2, MMP3, MMP9, PLA2G1B |
BP | Unclassified; | GO:0044236; multicellular organism metabolic process | 1.213E-06 | 8.307E-05 | HIF1A, MMP1, MMP12, MMP13, MMP2, MMP3, MMP9, PLA2G1B |
BP | GO:0008152; metabolic process | GO:0038083; peptidyl-tyrosine autophosphorylation | 1.239E-06 | 8.433E-05 | ABL1, EGFR, IGF1R, KDR, PTK2, SRC |
CC | GO:0016020; membrane | GO:0016323; basolateral plasma membrane | 1.271E-06 | 8.566E-05 | ABCC1, ADORA1, CA2, CA4, CA9, EGFR, HPGD, SLCO1B1, SLCO1B3, TSHR |
BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 1.361E-06 | 9.122E-05 | CYP1A2, CYP2C8, CYP2C9, CYP3A4 |
MF | GO:0003824; catalytic activity | GO:0004674; protein serine/threonine kinase activity | 1.396E-06 | 9.322E-05 | AKT1, ALK, AURKB, CAMK2B, CDK1, CSNK2A1, DAPK1, EGFR, GSK3B, MAPK1, NEK2, NEK6, NUAK1, PIM1, PKN1 |
MF | GO:0005488; binding | GO:0051721; protein phosphatase 2A binding | 1.776E-06 | 1.145E-04 | AKT1, BCL2, MAPT, PTPN1, TP53 |
BP | GO:0050896; response to stimulus | GO:0050728; negative regulation of inflammatory response | 2.250E-06 | 1.404E-04 | ADORA1, ADORA2A, CYP19A1, FFAR4, NFKB1, PPARA, PPARD, PPARG |
MF | Unclassified; | GO:0004872; receptor activity | 2.973E-06 | 1.798E-04 | ADORA1, ADORA2A, ADORA3, ALK, AXL, CXCR1, DRD4, EGFR, ESR1, ESR2, ESRRA, ESRRB, FFAR1, FFAR4, FLT3, HCAR2, HPGD, IGF1R, KCNH2, KDR, MET, NPC1, NPSR1, NR1I2, PPARA, PPARD, PPARG, TLR2, TSHR |
BP | GO:0009987; cellular process | GO:0071276; cellular response to cadmium ion | 3.017E-06 | 1.815E-04 | AKT1, CYP1A2, EGFR, MAPK1, MMP9 |
BP | GO:0008152; metabolic process | GO:0006367; transcription initiation from RNA polymerase II promoter | 3.031E-06 | 1.818E-04 | CDK1, ESR1, ESR2, ESRRA, ESRRB, NR1I2, PPARA, PPARD, PPARG |
MF | GO:0005488; binding | GO:0042562; hormone binding | 3.207E-06 | 1.903E-04 | ACHE, ALDH1A1, EGFR, HSD17B1, IGF1R, PIK3R1, TTR |
BP | Unclassified; | GO:0044259; multicellular organismal macromolecule metabolic process | 3.469E-06 | 2.031E-04 | HIF1A, MMP1, MMP12, MMP13, MMP2, MMP3, MMP9 |
MF | GO:0005488; binding | GO:0005496; steroid binding | 3.469E-06 | 2.031E-04 | CYP3A4, ESR1, ESR2, ESRRA, ESRRB, HSD17B1, NPC1 |
MF | GO:0003824; catalytic activity | GO:0101020; estrogen 16-alpha-hydroxylase activity | 3.930E-06 | 2.282E-04 | CYP1A1, CYP2C8, CYP3A4 |
CC | GO:0044464; cell part | GO:0005829; cytosol | 3.961E-06 | 2.288E-04 | ABL1, ADK, AKR1B1, AKR1B10, AKT1, ALDH1A1, ALOX12, ALOX15, ALOX5, AOX1, APP, AURKB, BCL2, BLM, CA1, CA13, CA2, CA3, CA7, CAMK2B, CASP1, CASP7, CDK1, CSNK2A1, FABP2, FABP3, FABP4, FABP5, FLT3, GFER, GLO1, GSK3B, HIF1A, HPGD, HSD17B1, HTT, LMNA, MAPK1, MAPT, MCL1, NEK2, NEK6, NFKB1, PIK3R1, PIM1, PKN1, PLA2G1B, PPARG, PTK2, PTPN1, PYGL, RAB9A, SMN1, SMN2, SRC, STAT6, TK1, TNKS, TNKS2, TP53, XDH |
BP | GO:0065007; biological regulation | GO:0032212; positive regulation of telomere maintenance via telomerase | 4.853E-06 | 2.716E-04 | AURKB, MAPK1, NEK2, TNKS, TNKS2 |
BP | GO:0009987; cellular process | GO:2000811; negative regulation of anoikis | 4.892E-06 | 2.717E-04 | BCL2, MCL1, PTK2, SRC |
BP | GO:0008152; metabolic process | GO:0019372; lipoxygenase pathway | 4.892E-06 | 2.717E-04 | ALOX12, ALOX15, ALOX5, HPGD |
BP | GO:0009987; cellular process | GO:2001243; negative regulation of intrinsic apoptotic signaling pathway | 6.750E-06 | 3.620E-04 | AKT1, BCL2, HIF1A, MCL1, MMP9, PTPN1, SRC |
BP | GO:0008152; metabolic process | GO:0002933; lipid hydroxylation | 7.818E-06 | 4.112E-04 | CYP1A1, CYP2C8, CYP3A4 |
BP | GO:0051179; localization | GO:0042307; positive regulation of protein import into nucleus | 8.297E-06 | 4.343E-04 | APP, CDK1, EGFR, MAPK1, PARP1, PIK3R1, TLR2 |
BP | GO:0008152; metabolic process | GO:0030574; collagen catabolic process | 8.546E-06 | 4.463E-04 | MMP1, MMP12, MMP13, MMP2, MMP3, MMP9 |
BP | GO:0048511; rhythmic process | GO:0048511; rhythmic process | 8.879E-06 | 4.612E-04 | AXL, BCL2, CSNK2A1, DRD4, EGFR, ESR1, GSK3B, PPARA, PPARG, SRC, TP53 |
BP | GO:0009987; cellular process | GO:0008630; intrinsic apoptotic signaling pathway in response to DNA damage | 1.112E-05 | 5.631E-04 | ABL1, BCL2, MCL1, PIK3R1, POLB, TP53 |
MF | GO:0005488; binding | GO:0002039; p53 binding | 1.316E-05 | 6.573E-04 | BLM, GSK3B, HIF1A, HTT, NUAK1, TP53 |
MF | GO:0098772; molecular function regulator | GO:0030235; nitric-oxide synthase regulator activity | 1.361E-05 | 6.673E-04 | AKT1, EGFR, ESR1 |
MF | GO:0060089; molecular transducer activity | GO:0001609; G-protein coupled adenosine receptor activity | 1.361E-05 | 6.673E-04 | ADORA1, ADORA2A, ADORA3 |
CC | GO:0016020; membrane | GO:0005789; endoplasmic reticulum membrane | 1.507E-05 | 7.291E-04 | BCL2, CAMK2B, CDK1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C8, CYP2C9, CYP3A4, EGFR, FAAH, HSD11B1, HSD17B2, NOX4, PTGS1, RAB9A, SLC28A3, TBXAS1 |
BP | GO:0050896; response to stimulus | GO:0055093; response to hyperoxia | 1.563E-05 | 7.496E-04 | CYP1A1, POLB, PPARG, TP53 |
BP | GO:0009987; cellular process | GO:0070374; positive regulation of ERK1 and ERK2 cascade | 1.634E-05 | 7.804E-04 | ABL1, ALOX15, APP, EGFR, FFAR4, KDR, NOX4, SRC, THPO |
BP | GO:0002376; immune system process | GO:0002684; positive regulation of immune system process | 1.758E-05 | 8.338E-04 | ABL1, AKT1, APP, AXL, BCL2, CA2, CD38, HCAR2, HIF1A, MAPK1, MMP12, MMP2, NFKB1, PIK3R1, PLA2G1B, PTK2, SRC, STAT6, THPO, TLR2, TP53 |
BP | GO:0009987; cellular process | GO:0051897; positive regulation of protein kinase B signaling | 1.772E-05 | 8.387E-04 | AXL, EGFR, MET, NOX4, PIK3R1, PTK2, SRC, THPO |
MF | GO:0003824; catalytic activity | GO:0016903; oxidoreductase activity, acting on the aldehyde or oxo group of donors | 1.785E-05 | 8.429E-04 | AKR1B1, AKR1B10, ALDH1A1, AOX1, XDH |
BP | GO:0008283; cell proliferation | GO:1904707; positive regulation of vascular smooth muscle cell proliferation | 1.899E-05 | 8.913E-04 | HPGD, MMP2, MMP9, TERT |
MF | GO:0005488; binding | GO:0046982; protein heterodimerization activity | 1.991E-05 | 9.282E-04 | ADORA1, ADORA2A, AXL, BCL2, EGFR, HIF1A, MCL1, NFKB1, PIK3R1, PPARD, PPARG, TLR2, TP53, TTR |
BP | GO:0032502; developmental process | GO:0031100; animal organ regeneration | 2.116E-05 | 9.762E-04 | AXL, CDK1, CSNK2A1, EGFR, FLT3, PPARG |
BP | GO:0009987; cellular process | GO:1903376; regulation of oxidative stress-induced neuron intrinsic apoptotic signaling pathway | 2.165E-05 | 9.926E-04 | HIF1A, MCL1, PARP1 |
BP | GO:0032501; multicellular organismal process | GO:0001503; ossification | 2.237E-05 | 1.017E-03 | ALOX15, ALPL, BCL2, EGFR, MMP13, MMP2, MMP9 |
BP | GO:0009987; cellular process | GO:1901216; positive regulation of neuron death | 2.281E-05 | 1.030E-03 | ABL1, GSK3B, MAPT, MCL1, PARP1, TP53 |
MF | Unclassified; | GO:0032403; protein complex binding | 2.420E-05 | 1.089E-03 | ABL1, ACHE, ADORA1, APEX1, EGFR, ESRRB, FLT3, IGF1R, KDR, MMP12, MMP13, MMP9, PIK3R1, PPARA, PTPN1, SRC, TLR2, TSHR |
BP | GO:0002376; immune system process | GO:0002521; leukocyte differentiation | 2.525E-05 | 1.127E-03 | ABL1, AXL, BCL2, FLT3, FUT7, GLO1, MMP9, PARP1, PIK3R1, PPARG |
CC | GO:0044464; cell part | GO:0005739; mitochondrion | 2.613E-05 | 1.154E-03 | ABL1, AKT1, APEX1, BCL2, CA5A, CA5B, CASP1, CDK1, CYP1A1, CYP1B1, ESR2, GFER, GSK3B, HSD17B10, MAOA, MAPK1, MCL1, MMP2, MPO, NFKB1, NOX4, PARP1, SRC, TP53 |
BP | GO:0009987; cellular process | GO:0022617; extracellular matrix disassembly | 2.642E-05 | 1.164E-03 | MMP1, MMP12, MMP13, MMP2, MMP3, MMP9 |
BP | GO:0050896; response to stimulus | GO:0070542; response to fatty acid | 2.839E-05 | 1.231E-03 | AKT1, FABP3, FFAR1, PPARG, SRC, TLR2 |
BP | GO:0065007; biological regulation | GO:0060249; anatomical structure homeostasis | 3.065E-05 | 1.319E-03 | AKR1B1, APEX1, BCL2, BLM, GAA, HIF1A, NOX4, PARP1, SRC, TERT |
BP | GO:0008152; metabolic process | GO:0019433; triglyceride catabolic process | 3.228E-05 | 1.379E-03 | FABP2, FABP3, FABP4, FABP5 |
BP | GO:0009987; cellular process | GO:0000733; DNA strand renaturation | 3.230E-05 | 1.379E-03 | BLM, RECQL, TP53 |
BP | GO:0009987; cellular process | GO:0001973; adenosine receptor signaling pathway | 3.230E-05 | 1.379E-03 | ADORA1, ADORA2A, ADORA3 |
BP | GO:0065007; biological regulation | GO:1904357; negative regulation of telomere maintenance via telomere lengthening | 4.428E-05 | 1.822E-03 | PARP1, SRC, TNKS, TNKS2 |
BP | GO:0050896; response to stimulus | GO:1904646; cellular response to amyloid-beta | 4.428E-05 | 1.822E-03 | APP, GSK3B, IGF1R, PARP1 |
MF | GO:0003824; catalytic activity | GO:0033764; steroid dehydrogenase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor | 4.428E-05 | 1.822E-03 | HSD11B1, HSD17B1, HSD17B10, HSD17B2 |
BP | GO:0008152; metabolic process | GO:0051974; negative regulation of telomerase activity | 4.590E-05 | 1.879E-03 | PPARG, SRC, TP53 |
BP | GO:0051179; localization | GO:0042908; xenobiotic transport | 4.590E-05 | 1.879E-03 | ABCC1, ABCG2, NR1I2 |
BP | GO:0050896; response to stimulus | GO:0010332; response to gamma radiation | 4.897E-05 | 1.982E-03 | BCL2, NOX4, PARP1, POLB, TP53 |
BP | GO:0008152; metabolic process | GO:0046320; regulation of fatty acid oxidation | 5.136E-05 | 2.056E-03 | AKT1, FABP3, PPARA, PPARG |
BP | GO:0008152; metabolic process | GO:0009115; xanthine catabolic process | 5.443E-05 | 2.124E-03 | AOX1, XDH |
BP | GO:0051179; localization | GO:0015860; purine nucleoside transmembrane transport | 5.443E-05 | 2.124E-03 | SLC28A2, SLC28A3 |
BP | GO:0009987; cellular process | GO:0006286; base-excision repair, base-free sugar-phosphate removal | 5.443E-05 | 2.124E-03 | APEX1, POLB |
BP | GO:0008152; metabolic process | GO:2001303; lipoxin A4 biosynthetic process | 5.443E-05 | 2.124E-03 | ALOX12, ALOX15 |
MF | GO:0060089; molecular transducer activity | GO:0038052; RNA polymerase II transcription factor activity, estrogen-activated sequence-specific DNA binding | 5.443E-05 | 2.124E-03 | ESR1, ESR2 |
MF | GO:0005215; transporter activity | GO:0015389; pyrimidine- and adenine-specific:sodium symporter activity | 5.443E-05 | 2.124E-03 | SLC28A1, SLC28A3 |
MF | GO:0003824; catalytic activity | GO:0047977; hepoxilin-epoxide hydrolase activity | 5.443E-05 | 2.124E-03 | ALOX12, ALOX15 |
MF | GO:0005215; transporter activity | GO:0015211; purine nucleoside transmembrane transporter activity | 5.443E-05 | 2.124E-03 | SLC28A2, SLC28A3 |
BP | GO:0008152; metabolic process | GO:2000379; positive regulation of reactive oxygen species metabolic process | 5.536E-05 | 2.153E-03 | AKT1, EGFR, MAPT, NOX4, TP53, XDH |
MF | GO:0005488; binding | GO:0034452; dynactin binding | 6.277E-05 | 2.406E-03 | GSK3B, HTT, MAPT |
BP | GO:0008283; cell proliferation | GO:0008285; negative regulation of cell proliferation | 6.760E-05 | 2.582E-03 | ADORA1, ADORA2A, ADORA3, APP, BCL2, CYP1B1, FABP3, LMNA, NOX4, PKN1, PPARD, PPARG, TERT, TLR2, TP53, XDH |
BP | GO:0009987; cellular process | GO:1901215; negative regulation of neuron death | 7.471E-05 | 2.805E-03 | ADORA2A, AKT1, AXL, BCL2, GSK3B, HIF1A, PPARA, TERT |
BP | GO:0008283; cell proliferation | GO:0033598; mammary gland epithelial cell proliferation | 8.323E-05 | 3.077E-03 | ESR1, MAPK1, STAT6 |
BP | GO:0065007; biological regulation | GO:0051091; positive regulation of DNA binding transcription factor activity | 8.404E-05 | 3.096E-03 | AKT1, ALK, APP, ESR1, ESR2, NFKB1, PLA2G1B, PPARG, TLR2 |
MF | GO:0005488; binding | GO:0051879; Hsp90 protein binding | 8.815E-05 | 3.215E-03 | CSNK2A1, HIF1A, KDR, MAPT |
BP | GO:0048511; rhythmic process | GO:0042752; regulation of circadian rhythm | 8.917E-05 | 3.247E-03 | ADORA1, ADORA2A, DRD4, PPARA, PPARG, TP53 |
BP | GO:0065007; biological regulation | GO:0000187; activation of MAPK activity | 9.508E-05 | 3.451E-03 | ALK, CDK1, DRD4, MAPK1, PKN1, PLA2G1B, PTPN1 |
BP | Unclassified; | GO:0032845; negative regulation of homeostatic process | 9.933E-05 | 3.583E-03 | ADORA1, BCL2, CD38, PARP1, SRC, TNKS, TNKS2 |
MF | GO:0005215; transporter activity | GO:0005319; lipid transporter activity | 9.933E-05 | 3.583E-03 | ABCC1, ABCG2, FABP3, HTT, NPC1, SLCO1B1, SLCO1B3 |
BP | GO:0008152; metabolic process | GO:0010907; positive regulation of glucose metabolic process | 9.974E-05 | 3.584E-03 | AKT1, ESRRB, PPARA, SRC |
BP | GO:0008152; metabolic process | GO:0006703; estrogen biosynthetic process | 1.076E-04 | 3.798E-03 | CYP19A1, HSD17B1, HSD17B2 |
BP | GO:0023052; signaling | GO:0032230; positive regulation of synaptic transmission, GABAergic | 1.076E-04 | 3.798E-03 | ADORA2A, CA2, CA7 |
BP | GO:0009987; cellular process | GO:2001240; negative regulation of extrinsic apoptotic signaling pathway in absence of ligand | 1.124E-04 | 3.928E-03 | AKT1, BCL2, MCL1, TERT |
CC | GO:0044425; membrane part | GO:0005887; integral component of plasma membrane | 1.217E-04 | 4.214E-03 | ABCC1, ADORA1, ADORA2A, ADORA3, ALK, APP, AXL, BACE1, DRD4, FFAR1, FFAR4, FLT3, IGF1R, KDR, MET, NPC1, NPSR1, SLC28A1, SLC28A2, SLC28A3, SLCO1B1, SLCO1B3, TLR2, TSHR |
BP | GO:0032502; developmental process | GO:0060065; uterus development | 1.362E-04 | 4.694E-03 | CYP19A1, ESR1, SRC |
BP | GO:0040011; locomotion | GO:0014911; positive regulation of smooth muscle cell migration | 1.411E-04 | 4.816E-03 | BCL2, NOX4, SRC, TERT |
BP | GO:0065007; biological regulation | GO:0045124; regulation of bone resorption | 1.411E-04 | 4.816E-03 | CA2, CD38, EGFR, SRC |
BP | GO:0065007; biological regulation | GO:0048167; regulation of synaptic plasticity | 1.509E-04 | 5.112E-03 | ABL1, ADORA1, ADORA2A, APP, CAMK2B, CD38, MAPK1 |
MF | GO:0003824; catalytic activity | GO:0009055; electron transfer activity | 1.526E-04 | 5.148E-03 | AKR1B1, AOX1, CYP19A1, CYP1A2, NOX4, XDH |
BP | GO:0032501; multicellular organismal process | GO:0014005; microglia development | 1.625E-04 | 5.312E-03 | APP, TLR2 |
BP | GO:0051179; localization | GO:1904823; purine nucleobase transmembrane transport | 1.625E-04 | 5.312E-03 | SLC28A1, SLC28A3 |
BP | GO:0008152; metabolic process | GO:0000023; maltose metabolic process | 1.625E-04 | 5.312E-03 | GAA, MGAM |
BP | GO:0002376; immune system process | GO:0001922; B-1 B cell homeostasis | 1.625E-04 | 5.312E-03 | ABL1, HIF1A |
BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 1.625E-04 | 5.312E-03 | CA2, CA7 |
BP | GO:0051179; localization | GO:0015855; pyrimidine nucleobase transport | 1.625E-04 | 5.312E-03 | SLC28A1, SLC28A3 |
MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 1.625E-04 | 5.312E-03 | CYP1A1, CYP3A4 |
MF | GO:0003824; catalytic activity | GO:0004052; arachidonate 12-lipoxygenase activity | 1.625E-04 | 5.312E-03 | ALOX12, ALOX15 |
MF | GO:0003824; catalytic activity | GO:0032450; maltose alpha-glucosidase activity | 1.625E-04 | 5.312E-03 | GAA, MGAM |
MF | GO:0003824; catalytic activity | GO:0051120; hepoxilin A3 synthase activity | 1.625E-04 | 5.312E-03 | ALOX12, ALOX15 |
CC | GO:0044464; cell part | GO:0099056; integral component of presynaptic membrane | 1.625E-04 | 5.312E-03 | ADORA1, ADORA2A |
BP | GO:0051179; localization | GO:0070198; protein localization to chromosome, telomeric region | 1.694E-04 | 5.512E-03 | TERT, TNKS, TNKS2 |
BP | GO:0009987; cellular process | GO:0097194; execution phase of apoptosis | 1.748E-04 | 5.640E-03 | AKT1, CASP1, CASP7, PTK2 |
BP | GO:0008152; metabolic process | GO:0031331; positive regulation of cellular catabolic process | 1.762E-04 | 5.675E-03 | AKT1, CDK1, DAPK1, ESRRB, GSK3B, HIF1A, HTT, KDR, PPARA, PTK2, PTPN1 |
BP | GO:0032501; multicellular organismal process | GO:2000026; regulation of multicellular organismal development | 1.779E-04 | 5.713E-03 | ABL1, AKT1, ALOX12, APP, AXL, BCL2, CA2, CAMK2B, CDK1, CYP1B1, EGFR, ESR1, ESRRA, GSK3B, HIF1A, KDR, L3MBTL1, MAPT, PIK3R1, PIM1, PPARD, PPARG, PTK2, SRC, STAT6, TERT, THPO, TLR2, XDH |
BP | GO:0008152; metabolic process | GO:0010507; negative regulation of autophagy | 1.823E-04 | 5.846E-03 | AKT1, BCL2, MCL1, MET, NPC1 |
BP | GO:0065007; biological regulation | GO:0042593; glucose homeostasis | 1.839E-04 | 5.880E-03 | AKT1, FFAR1, HIF1A, NOX4, PIK3R1, PPARG, PYGL |
BP | GO:0009987; cellular process | GO:0048010; vascular endothelial growth factor receptor signaling pathway | 1.947E-04 | 6.190E-03 | AXL, KDR, PIK3R1, PTK2, SRC |
BP | GO:0065007; biological regulation | GO:0051101; regulation of DNA binding | 1.955E-04 | 6.205E-03 | MMP9, NEK2, PARP1, PPARA, PPARG, TNKS |
BP | GO:0050896; response to stimulus | GO:0070920; regulation of production of small RNA involved in gene silencing by RNA | 2.073E-04 | 6.524E-03 | EGFR, ESR1, TERT |
BP | GO:0032501; multicellular organismal process | GO:0048546; digestive tract morphogenesis | 2.073E-04 | 6.524E-03 | BCL2, EGFR, HIF1A |
CC | GO:0044464; cell part | GO:0030673; axolemma | 2.073E-04 | 6.524E-03 | ADORA1, ADORA2A, MAPT |
MF | GO:0003824; catalytic activity | GO:0004222; metalloendopeptidase activity | 2.151E-04 | 6.710E-03 | MMP1, MMP12, MMP13, MMP2, MMP3, MMP9 |
BP | GO:0050896; response to stimulus | GO:0071214; cellular response to abiotic stimulus | 2.192E-04 | 6.809E-03 | AKT1, AURKB, BLM, CASP1, EGFR, NFKB1, NOX4, PIK3R1, TP53 |
BP | GO:0051179; localization | GO:0030100; regulation of endocytosis | 2.303E-04 | 7.123E-03 | ABL1, ALOX15, APP, AXL, PPARG, PTPN1, SRC, TLR2 |
BP | GO:0008152; metabolic process | GO:0046209; nitric oxide metabolic process | 2.504E-04 | 7.657E-03 | AKT1, CYP1B1, TLR2 |
BP | GO:0050896; response to stimulus | GO:0033189; response to vitamin A | 2.504E-04 | 7.657E-03 | CYP1A1, PPARD, PPARG |
MF | GO:0003824; catalytic activity | GO:0008392; arachidonic acid epoxygenase activity | 2.504E-04 | 7.657E-03 | CYP2C19, CYP2C8, CYP2C9 |
MF | GO:0003824; catalytic activity | GO:0035173; histone kinase activity | 2.504E-04 | 7.657E-03 | AURKB, CDK1, PKN1 |
BP | GO:0002376; immune system process | GO:0043312; neutrophil degranulation | 2.517E-04 | 7.675E-03 | ALOX5, CXCR1, FABP5, GAA, MAPK1, MGAM, MMP9, MPO, NFKB1, PYGL, TLR2, TTR |
BP | GO:0050896; response to stimulus | GO:0071496; cellular response to external stimulus | 2.638E-04 | 7.989E-03 | AKT1, AXL, BCL2, CASP1, EGFR, MAPK1, NFKB1, PPARG, TP53 |
BP | GO:0050896; response to stimulus | GO:0042060; wound healing | 2.670E-04 | 8.071E-03 | ALOX15, EGFR, PPARA, PPARD, TP53 |
MF | GO:0005488; binding | GO:0042803; protein homodimerization activity | 2.718E-04 | 8.185E-03 | ABCG2, ACHE, AKT1, AOX1, BCL2, BLM, CAMK2B, FLT3, HPGD, KCNH2, MAPT, MCL1, NFKB1, PYGL, TERT, XDH |
BP | GO:0009987; cellular process | GO:0001961; positive regulation of cytokine-mediated signaling pathway | 2.840E-04 | 8.495E-03 | AXL, CASP1, HIF1A, MMP12 |
BP | GO:0008152; metabolic process | GO:0051000; positive regulation of nitric-oxide synthase activity | 2.988E-04 | 8.853E-03 | AKT1, HIF1A, TERT |
BP | GO:0050896; response to stimulus | GO:0031000; response to caffeine | 2.988E-04 | 8.853E-03 | ADORA2A, PPARG, TP53 |
BP | GO:0032501; multicellular organismal process | GO:0043536; positive regulation of blood vessel endothelial cell migration | 3.106E-04 | 9.141E-03 | ABL1, AKT1, HIF1A, KDR |
BP | GO:0032501; multicellular organismal process | GO:0097746; regulation of blood vessel diameter | 3.233E-04 | 9.315E-03 | ADORA1, ADORA2A, AKT1, CD38, EGFR, PPARD |
BP | GO:0050896; response to stimulus | GO:0032355; response to estradiol | 3.233E-04 | 9.315E-03 | CD38, CYP1A2, EGFR, ESR1, ESRRA, HPGD |
BP | GO:0065007; biological regulation | GO:0032431; activation of phospholipase A2 activity | 3.234E-04 | 9.315E-03 | EGFR, PLA2G1B |
BP | GO:0008152; metabolic process | GO:0070213; protein auto-ADP-ribosylation | 3.234E-04 | 9.315E-03 | TNKS, TNKS2 |
BP | GO:0032501; multicellular organismal process | GO:0032640; tumor necrosis factor production | 3.234E-04 | 9.315E-03 | APP, TLR2 |
BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 3.234E-04 | 9.315E-03 | CYP1A1, CYP1A2 |
MF | GO:0005488; binding | GO:0034056; estrogen response element binding | 3.234E-04 | 9.315E-03 | ESR1, ESR2 |
MF | GO:0003824; catalytic activity | GO:0004558; alpha-1,4-glucosidase activity | 3.234E-04 | 9.315E-03 | GAA, MGAM |
CC | GO:0044464; cell part | GO:0048471; perinuclear region of cytoplasm | 3.243E-04 | 9.328E-03 | ABL1, ACHE, AKR1B1, APEX1, APP, CA4, EGFR, HTT, KCNH2, NOX4, NPC1, PPARG, SRC, TNKS2 |
BP | GO:0050896; response to stimulus | GO:1901655; cellular response to ketone | 3.381E-04 | 9.662E-03 | AKR1B1, AKT1, EGFR, PPARG, SRC |
BP | GO:0009987; cellular process | GO:0090199; regulation of release of cytochrome c from mitochondria | 3.390E-04 | 9.662E-03 | AKT1, LMNA, MMP9, TP53 |
BP | GO:0040007; growth | GO:0045926; negative regulation of growth | 3.396E-04 | 9.666E-03 | BCL2, ESR2, HIF1A, MPO, PPARD, PPARG, PTK2, TP53 |
CC | GO:0016020; membrane | GO:0045121; membrane raft | 3.404E-04 | 9.675E-03 | APP, BACE1, EGFR, KDR, MAPK1, NPC1, SRC, STAT6, TLR2 |
BP | GO:0009987; cellular process | GO:1901796; regulation of signal transduction by p53 class mediator | 3.419E-04 | 9.706E-03 | AKT1, AURKB, BLM, CSNK2A1, L3MBTL1, NUAK1, TP53 |
BP | GO:0032502; developmental process | GO:0045597; positive regulation of cell differentiation | 3.539E-04 | 9.995E-03 | ABL1, AKT1, APP, AXL, BCL2, CA2, CAMK2B, HIF1A, KDR, MAPT, NFKB1, PARP1, PPARD, PPARG, TERT, THPO, TLR2 |
MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 7.556E-24 | 7.644E-20 | CA1, CA12, CA13, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 2.919E-16 | 2.302E-13 | CA1, CA12, CA13, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
MF | GO:0005488; binding | GO:0008270; zinc ion binding | 7.169E-16 | 4.591E-13 | BLM, CA1, CA12, CA13, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, ESR1, ESR2, ESRRA, ESRRB, GLO1, L3MBTL1, MMP1, MMP12, MMP13, MMP2, MMP3, MMP9, NR1I2, PARP1, PPARA, PPARD, PPARG, PTPN1, TK1, TNKS, TP53 |
BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 1.271E-15 | 7.281E-13 | CA1, CA12, CA13, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|
hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 6.690E-23 | 1.345E-20 | CA12; CA1; CA3; CA5B; CA2; CA5A; CA4; CA7; CA6; CA9; CA14; CA13 |
hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 1.382E-12 | 1.389E-10 | CAMK2B; SRC; MMP2; PIK3R1; HIF1A; ESR1; MMP9; PTK2; EGFR; IGF1R; KDR; AKT1; MAPK1; TP53; MET; TLR2 |
hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 7.844E-12 | 5.255E-10 | GSK3B; FLT3; MMP1; DAPK1; MMP2; PIK3R1; HIF1A; MMP9; EGFR; NFKB1; PTK2; IGF1R; ABL1; BCL2; AKT1; MAPK1; PPARG; MET; TP53; PPARD |
hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 6.931E-10 | 2.322E-08 | PLA2G1B; MAOA; ALOX15; ADK; AKR1B1; ALOX12; PYGL; CYP2C19; CYP3A4; CYP19A1; HSD17B10; PTGS1; HSD11B1; FUT7; HSD17B1; ALOX5; HSD17B2; CD38; AOX1; TK1; XDH; MGAM; GAA; CYP2C9; CYP2C8; AKR1B10; TBXAS1; CYP1A2; ALDH1A1; CYP1A1; ALPL |
hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 5.571E-10 | 2.240E-08 | CYP2C9; CYP2C8; PLA2G1B; ALOX5; ALOX15; TBXAS1; ALOX12; CYP2C19; PTGS1 |
hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 4.390E-10 | 2.206E-08 | MMP1; DAPK1; SRC; MMP2; MAPK1; MMP9; TP53; EGFR |
hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 7.733E-09 | 1.776E-07 | CYP2C9; APP; CYP2C8; MAOA; ALOX5; ALOX15; MAPK1; ALOX12; CYP2C19; PTGS1 |
hsa04151 | PI3K-Akt signaling pathway_Homo sapiens_hsa04151 | 2.345E-08 | 3.928E-07 | GSK3B; PIK3R1; PTK2; EGFR; NFKB1; IGF1R; KDR; BCL2; AKT1; MAPK1; PKN1; TP53; MET; TLR2; MCL1 |
hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 1.483E-08 | 2.710E-07 | GSK3B; BCL2; AKT1; MAPK1; PIK3R1; TP53; EGFR; NFKB1; IGF1R |
hsa04012 | ErbB signaling pathway_Homo sapiens_hsa04012 | 1.211E-08 | 2.434E-07 | CAMK2B; GSK3B; SRC; ABL1; AKT1; MAPK1; PIK3R1; EGFR; PTK2 |
hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 1.128E-09 | 3.238E-08 | CYP2C9; CYP2C8; PLA2G1B; CYP1A2; ALOX15; CYP3A4; CYP2C19 |
hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 7.951E-09 | 1.776E-07 | HSD11B1; HSD17B1; CYP1A2; HSD17B2; CYP1A1; CYP1B1; CYP3A4; CYP19A1 |
hsa04915 | Estrogen signaling pathway_Homo sapiens_hsa04915 | 3.801E-08 | 5.094E-07 | SRC; MMP2; AKT1; MAPK1; PIK3R1; ESR1; MMP9; EGFR; ESR2 |
hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 2.563E-08 | 3.963E-07 | FLT3; AKT1; MAPK1; PIK3R1; TP53; MET; HIF1A; EGFR |
hsa04917 | Prolactin signaling pathway_Homo sapiens_hsa04917 | 4.564E-08 | 5.734E-07 | GSK3B; SRC; AKT1; MAPK1; PIK3R1; ESR1; NFKB1; ESR2 |
hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 6.615E-08 | 6.998E-07 | CASP7; PARP1; LMNA; BCL2; AKT1; MAPK1; PIK3R1; TP53; NFKB1; MCL1 |
hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 5.380E-08 | 6.361E-07 | CAMK2B; BCL2; AKT1; MAPK1; PIK3R1; HIF1A; EGFR; NFKB1; IGF1R |
hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 9.840E-08 | 9.418E-07 | SRC; BCL2; AKT1; MAPK1; STAT6; PIK3R1; TP53; MMP9; NFKB1; TLR2 |
hsa03320 | PPAR signaling pathway_Homo sapiens_hsa03320 | 3.247E-08 | 4.661E-07 | FABP2; FABP3; FABP4; FABP5; MMP1; PPARG; PPARA; PPARD |
hsa05202 | Transcriptional misregulation in cancer_Homo sapiens_hsa05202 | 7.130E-08 | 7.165E-07 | HPGD; FLT3; MMP3; PPARG; TP53; MPO; MMP9; MET; NFKB1; PTK2; IGF1R |
hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 6.367E-08 | 6.998E-07 | HSD17B1; ALOX5; HSD17B2; CYP1A1; CYP1B1; CYP19A1; IGF1R |
hsa04510 | Focal adhesion_Homo sapiens_hsa04510 | 2.296E-07 | 1.775E-06 | GSK3B; SRC; KDR; BCL2; AKT1; MAPK1; PIK3R1; MET; PTK2; EGFR; IGF1R |
hsa04722 | Neurotrophin signaling pathway_Homo sapiens_hsa04722 | 2.023E-07 | 1.626E-06 | CAMK2B; GSK3B; ABL1; BCL2; AKT1; MAPK1; PIK3R1; TP53; NFKB1 |
hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 2.023E-07 | 1.626E-06 | ABCC1; ADORA3; ADORA1; BCL2; AKT1; MAPK1; PIK3R1; TP53; NFKB1 |
hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 1.617E-07 | 1.413E-06 | FLT3; PIM1; AKT1; MAPK1; PIK3R1; NFKB1; PPARD |
hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 1.280E-07 | 1.169E-06 | HSD11B1; CYP2C9; CYP2C8; CYP1A2; CYP1A1; CYP1B1; CYP3A4; CYP2C19 |
hsa05214 | Glioma_Homo sapiens_hsa05214 | 4.059E-07 | 2.914E-06 | CAMK2B; AKT1; MAPK1; PIK3R1; TP53; EGFR; IGF1R |
hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 1.550E-06 | 9.733E-06 | ABCC1; PIM1; ABL1; BCL2; CYP1B1; MAPK1; TP53; MMP9; MET; EGFR; NFKB1; MCL1 |
hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 1.720E-06 | 1.048E-05 | HCAR2; CAMK2B; ADORA2A; ADORA1; AKT1; MAPK1; PIK3R1; PPARA; NFKB1; TSHR |
hsa05218 | Melanoma_Homo sapiens_hsa05218 | 7.482E-07 | 5.013E-06 | AKT1; MAPK1; PIK3R1; TP53; MET; EGFR; IGF1R |
hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 4.059E-07 | 2.914E-06 | CYP2C9; CYP2C8; CYP1A2; ALDH1A1; CYP1A1; AOX1; CYP3A4 |
hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 6.142E-07 | 4.257E-06 | CYP2C9; CYP2C8; MAOA; CYP1A2; AOX1; CYP3A4; CYP2C19 |
hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 2.117E-06 | 1.216E-05 | GSK3B; SRC; AKT1; MAPK1; PIK3R1; TP53; ESR1; HIF1A |
hsa04520 | Adherens junction_Homo sapiens_hsa04520 | 9.945E-07 | 6.448E-06 | PTPN1; CSNK2A1; SRC; MAPK1; MET; EGFR; IGF1R |
hsa04014 | Ras signaling pathway_Homo sapiens_hsa04014 | 5.575E-06 | 2.733E-05 | PLA2G1B; KDR; ABL1; AKT1; MAPK1; PIK3R1; MET; EGFR; NFKB1; IGF1R |
hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 5.181E-06 | 2.670E-05 | GSK3B; AKT1; MAPK1; PIK3R1; PPARA; TP53; EGFR; NFKB1 |
hsa05162 | Measles_Homo sapiens_hsa05162 | 6.113E-06 | 2.925E-05 | GSK3B; CSNK2A1; AKT1; RAB9A; PIK3R1; TP53; NFKB1; TLR2 |
hsa04933 | AGE-RAGE signaling pathway in diabetic complications_Homo sapiens_hsa04933 | 8.096E-06 | 3.698E-05 | MMP2; PIM1; BCL2; AKT1; MAPK1; PIK3R1; NFKB1 |
hsa05169 | Epstein-Barr virus infection_Homo sapiens_hsa05169 | 1.519E-05 | 6.108E-05 | GSK3B; CSNK2A1; BCL2; CDK1; AKT1; CD38; PIK3R1; TP53; NFKB1 |
hsa05223 | Non-small cell lung cancer_Homo sapiens_hsa05223 | 2.910E-06 | 1.581E-05 | ALK; AKT1; MAPK1; PIK3R1; TP53; EGFR |
hsa05213 | Endometrial cancer_Homo sapiens_hsa05213 | 1.868E-06 | 1.104E-05 | GSK3B; AKT1; MAPK1; PIK3R1; TP53; EGFR |
hsa04931 | Insulin resistance_Homo sapiens_hsa04931 | 1.337E-05 | 5.782E-05 | PTPN1; GSK3B; AKT1; PIK3R1; PYGL; PPARA; NFKB1 |
hsa04370 | VEGF signaling pathway_Homo sapiens_hsa04370 | 4.832E-06 | 2.556E-05 | SRC; KDR; AKT1; MAPK1; PIK3R1; PTK2 |
hsa04015 | Rap1 signaling pathway_Homo sapiens_hsa04015 | 2.147E-05 | 8.300E-05 | ADORA2A; SRC; KDR; AKT1; MAPK1; PIK3R1; MET; EGFR; IGF1R |
hsa04630 | Jak-STAT signaling pathway_Homo sapiens_hsa04630 | 1.832E-05 | 7.219E-05 | THPO; PIM1; BCL2; AKT1; AOX1; STAT6; PIK3R1; MCL1 |
hsa04668 | TNF signaling pathway_Homo sapiens_hsa04668 | 1.420E-05 | 5.824E-05 | CASP7; MMP3; AKT1; MAPK1; PIK3R1; MMP9; NFKB1 |
hsa04923 | Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | 2.910E-06 | 1.581E-05 | FABP4; ADORA1; AKT1; PIK3R1; TSHR; PTGS1 |
hsa05210 | Colorectal cancer_Homo sapiens_hsa05210 | 5.318E-06 | 2.672E-05 | GSK3B; BCL2; AKT1; MAPK1; PIK3R1; TP53 |
hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 7.678E-06 | 3.589E-05 | AKT1; MAPK1; PIK3R1; TP53; EGFR; NFKB1 |
hsa05145 | Toxoplasmosis_Homo sapiens_hsa05145 | 2.243E-05 | 8.508E-05 | ALOX5; BCL2; AKT1; MAPK1; PIK3R1; NFKB1; TLR2 |
hsa04062 | Chemokine signaling pathway_Homo sapiens_hsa04062 | 6.099E-05 | 2.151E-04 | GSK3B; CXCR1; SRC; AKT1; MAPK1; PIK3R1; NFKB1; PTK2 |
hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 1.381E-05 | 5.782E-05 | ABL1; AKT1; MAPK1; PIK3R1; TP53; NFKB1 |
hsa04211 | Longevity regulating pathway - mammal_Homo sapiens_hsa04211 | 5.841E-05 | 2.133E-04 | AKT1; PPARG; PIK3R1; TP53; NFKB1; IGF1R |
hsa04725 | Cholinergic synapse_Homo sapiens_hsa04725 | 1.471E-04 | 4.927E-04 | CAMK2B; ACHE; BCL2; AKT1; MAPK1; PIK3R1 |
hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 1.381E-05 | 5.782E-05 | HSD11B1; CYP2C9; CYP1A2; CYP1A1; CYP1B1; CYP3A4 |
hsa05010 | Alzheimer's disease_Homo sapiens_hsa05010 | 2.090E-04 | 6.667E-04 | BACE1; APP; GSK3B; CASP7; MAPK1; MAPT; HSD17B10 |
hsa05222 | Small cell lung cancer_Homo sapiens_hsa05222 | 3.534E-05 | 1.315E-04 | BCL2; AKT1; PIK3R1; TP53; NFKB1; PTK2 |
hsa04611 | Platelet activation_Homo sapiens_hsa04611 | 2.462E-04 | 7.733E-04 | SRC; TBXAS1; AKT1; MAPK1; PIK3R1; PTGS1 |
hsa05152 | Tuberculosis_Homo sapiens_hsa05152 | 2.974E-04 | 9.196E-04 | CAMK2B; SRC; BCL2; AKT1; MAPK1; NFKB1; TLR2 |
hsa05203 | Viral carcinogenesis_Homo sapiens_hsa05203 | 6.924E-04 | 1.938E-03 | POLB; SRC; CDK1; MAPK1; PIK3R1; TP53; NFKB1 |
hsa04910 | Insulin signaling pathway_Homo sapiens_hsa04910 | 4.954E-04 | 1.480E-03 | PTPN1; GSK3B; AKT1; MAPK1; PIK3R1; PYGL |
hsa04550 | Signaling pathways regulating pluripotency of stem cells_Homo sapiens_hsa04550 | 5.547E-04 | 1.616E-03 | GSK3B; ESRRB; AKT1; MAPK1; PIK3R1; IGF1R |
hsa04932 | Non-alcoholic fatty liver disease (NAFLD)_Homo sapiens_hsa04932 | 7.661E-04 | 2.109E-03 | GSK3B; CASP7; AKT1; PIK3R1; PPARA; NFKB1 |
hsa04912 | GnRH signaling pathway_Homo sapiens_hsa04912 | 4.947E-04 | 1.480E-03 | CAMK2B; SRC; MMP2; MAPK1; EGFR |
hsa04921 | Oxytocin signaling pathway_Homo sapiens_hsa04921 | 9.697E-04 | 2.499E-03 | CAMK2B; SRC; CD38; MAPK1; PIK3R1; EGFR |
hsa04914 | Progesterone-mediated oocyte maturation_Homo sapiens_hsa04914 | 6.941E-04 | 1.938E-03 | CDK1; AKT1; MAPK1; PIK3R1; IGF1R |
hsa04662 | B cell receptor signaling pathway_Homo sapiens_hsa04662 | 1.771E-04 | 5.740E-04 | GSK3B; AKT1; MAPK1; PIK3R1; NFKB1 |
hsa05164 | Influenza A_Homo sapiens_hsa05164 | 1.637E-03 | 4.014E-03 | GSK3B; CASP1; AKT1; MAPK1; PIK3R1; NFKB1 |
hsa05231 | Choline metabolism in cancer_Homo sapiens_hsa05231 | 7.958E-04 | 2.162E-03 | AKT1; MAPK1; PIK3R1; HIF1A; EGFR |
hsa05211 | Renal cell carcinoma_Homo sapiens_hsa05211 | 1.097E-04 | 3.800E-04 | AKT1; MAPK1; PIK3R1; MET; HIF1A |
hsa05166 | HTLV-I infection_Homo sapiens_hsa05166 | 2.590E-03 | 5.886E-03 | POLB; GSK3B; TERT; AKT1; PIK3R1; TP53; NFKB1 |
hsa05142 | Chagas disease (American trypanosomiasis)_Homo sapiens_hsa05142 | 9.083E-04 | 2.371E-03 | AKT1; MAPK1; PIK3R1; NFKB1; TLR2 |
hsa04620 | Toll-like receptor signaling pathway_Homo sapiens_hsa04620 | 9.896E-04 | 2.518E-03 | AKT1; MAPK1; PIK3R1; NFKB1; TLR2 |
hsa04660 | T cell receptor signaling pathway_Homo sapiens_hsa04660 | 9.083E-04 | 2.371E-03 | GSK3B; AKT1; MAPK1; PIK3R1; NFKB1 |
hsa05120 | Epithelial cell signaling in Helicobacter pylori infection_Homo sapiens_hsa05120 | 1.264E-04 | 4.308E-04 | CXCR1; SRC; MET; EGFR; NFKB1 |
hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 1.552E-04 | 5.115E-04 | SLCO1B1; CA2; SLCO1B3; CYP3A4; ABCG2 |
hsa04728 | Dopaminergic synapse_Homo sapiens_hsa04728 | 2.359E-03 | 5.483E-03 | CAMK2B; GSK3B; MAOA; AKT1; DRD4 |
hsa04360 | Axon guidance_Homo sapiens_hsa04360 | 2.203E-03 | 5.211E-03 | GSK3B; ABL1; MAPK1; MET; PTK2 |
hsa04310 | Wnt signaling pathway_Homo sapiens_hsa04310 | 3.567E-03 | 7.794E-03 | CAMK2B; GSK3B; CSNK2A1; TP53; PPARD |
hsa04380 | Osteoclast differentiation_Homo sapiens_hsa04380 | 2.606E-03 | 5.886E-03 | AKT1; MAPK1; PPARG; PIK3R1; NFKB1 |
hsa04068 | FoxO signaling pathway_Homo sapiens_hsa04068 | 2.693E-03 | 6.013E-03 | AKT1; MAPK1; PIK3R1; EGFR; IGF1R |
hsa04072 | Phospholipase D signaling pathway_Homo sapiens_hsa04072 | 3.786E-03 | 8.096E-03 | CXCR1; AKT1; MAPK1; PIK3R1; EGFR |
hsa04261 | Adrenergic signaling in cardiomyocytes_Homo sapiens_hsa04261 | 4.253E-03 | 8.905E-03 | CAMK2B; BCL2; AKT1; MAPK1; PIK3R1 |
hsa04010 | MAPK signaling pathway_Homo sapiens_hsa04010 | 1.015E-02 | 1.925E-02 | AKT1; MAPK1; MAPT; TP53; EGFR; NFKB1 |
hsa04144 | Endocytosis_Homo sapiens_hsa04144 | 1.090E-02 | 1.992E-02 | CXCR1; SRC; KDR; MET; EGFR; IGF1R |
hsa05168 | Herpes simplex infection_Homo sapiens_hsa05168 | 1.068E-02 | 1.988E-02 | CSNK2A1; CDK1; TP53; NFKB1; TLR2 |
hsa04022 | cGMP-PKG signaling pathway_Homo sapiens_hsa04022 | 7.044E-03 | 1.375E-02 | ADORA3; ADORA1; AKT1; MAPK1; PIK3R1 |
hsa04060 | Cytokine-cytokine receptor interaction_Homo sapiens_hsa04060 | 1.210E-02 | 2.103E-02 | CXCR1; THPO; FLT3; KDR; MET; EGFR |
hsa04810 | Regulation of actin cytoskeleton_Homo sapiens_hsa04810 | 1.895E-02 | 3.122E-02 | SRC; MAPK1; PIK3R1; PTK2; EGFR |
hsa04750 | Inflammatory mediator regulation of TRP channels_Homo sapiens_hsa04750 | 5.386E-03 | 1.093E-02 | CAMK2B; SRC; ALOX12; PIK3R1 |
hsa04670 | Leukocyte transendothelial migration_Homo sapiens_hsa04670 | 1.026E-02 | 1.927E-02 | MMP2; PIK3R1; MMP9; PTK2 |
hsa04922 | Glucagon signaling pathway_Homo sapiens_hsa04922 | 5.988E-03 | 1.180E-02 | CAMK2B; AKT1; PYGL; PPARA |
hsa05146 | Amoebiasis_Homo sapiens_hsa05146 | 5.783E-03 | 1.154E-02 | PIK3R1; NFKB1; PTK2; TLR2 |
hsa04114 | Oocyte meiosis_Homo sapiens_hsa04114 | 1.181E-02 | 2.101E-02 | CAMK2B; CDK1; MAPK1; IGF1R |
hsa04110 | Cell cycle_Homo sapiens_hsa04110 | 1.214E-02 | 2.103E-02 | GSK3B; ABL1; CDK1; TP53 |
hsa04152 | AMPK signaling pathway_Homo sapiens_hsa04152 | 1.214E-02 | 2.103E-02 | AKT1; PPARG; PIK3R1; IGF1R |
hsa04540 | Gap junction_Homo sapiens_hsa04540 | 3.672E-03 | 7.937E-03 | SRC; CDK1; MAPK1; EGFR |
hsa04064 | NF-kappa B signaling pathway_Homo sapiens_hsa04064 | 4.474E-03 | 9.176E-03 | CSNK2A1; PARP1; BCL2; NFKB1 |
hsa05132 | Salmonella infection_Homo sapiens_hsa05132 | 3.381E-03 | 7.468E-03 | CASP1; MAPK1; PKN1; NFKB1 |
hsa05100 | Bacterial invasion of epithelial cells_Homo sapiens_hsa05100 | 2.373E-03 | 5.483E-03 | SRC; PIK3R1; MET; PTK2 |
hsa05133 | Pertussis_Homo sapiens_hsa05133 | 2.056E-03 | 4.919E-03 | CASP7; CASP1; MAPK1; NFKB1 |
hsa04150 | mTOR signaling pathway_Homo sapiens_hsa04150 | 8.958E-04 | 2.371E-03 | AKT1; MAPK1; PIK3R1; HIF1A |
hsa04666 | Fc gamma R-mediated phagocytosis_Homo sapiens_hsa04666 | 2.912E-02 | 4.573E-02 | AKT1; MAPK1; PIK3R1 |
hsa04972 | Pancreatic secretion_Homo sapiens_hsa04972 | 3.158E-02 | 4.895E-02 | CA2; PLA2G1B; CD38 |
hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 9.371E-06 | 4.186E-05 | MAOA; CYP1A2; CYP1A1; AOX1; CYP1B1 |
hsa05323 | Rheumatoid arthritis_Homo sapiens_hsa05323 | 2.677E-02 | 4.271E-02 | MMP1; MMP3; TLR2 |
hsa04640 | Hematopoietic cell lineage_Homo sapiens_hsa04640 | 2.526E-02 | 4.095E-02 | THPO; FLT3; CD38 |
hsa05134 | Legionellosis_Homo sapiens_hsa05134 | 6.440E-04 | 1.849E-03 | CASP7; CASP1; NFKB1; TLR2 |
hsa05131 | Shigellosis_Homo sapiens_hsa05131 | 1.210E-03 | 3.002E-03 | SRC; ABL1; MAPK1; NFKB1 |
hsa05140 | Leishmaniasis_Homo sapiens_hsa05140 | 1.546E-02 | 2.612E-02 | MAPK1; NFKB1; TLR2 |
hsa04664 | Fc epsilon RI signaling pathway_Homo sapiens_hsa04664 | 1.279E-02 | 2.196E-02 | AKT1; MAPK1; PIK3R1 |
hsa04920 | Adipocytokine signaling pathway_Homo sapiens_hsa04920 | 1.382E-02 | 2.354E-02 | AKT1; PPARA; NFKB1 |
hsa04213 | Longevity regulating pathway - multiple species_Homo sapiens_hsa04213 | 1.085E-02 | 1.992E-02 | AKT1; PIK3R1; IGF1R |
hsa05321 | Inflammatory bowel disease (IBD)_Homo sapiens_hsa05321 | 1.132E-02 | 2.049E-02 | STAT6; NFKB1; TLR2 |
hsa04621 | NOD-like receptor signaling pathway_Homo sapiens_hsa04621 | 7.901E-03 | 1.512E-02 | CASP1; MAPK1; NFKB1 |
hsa00500 | Starch and sucrose metabolism_Homo sapiens_hsa00500 | 7.524E-03 | 1.454E-02 | MGAM; GAA; PYGL |
hsa05014 | Amyotrophic lateral sclerosis (ALS)_Homo sapiens_hsa05014 | 5.801E-03 | 1.154E-02 | BCL2; CASP1; TP53 |
hsa04973 | Carbohydrate digestion and absorption_Homo sapiens_hsa04973 | 4.078E-03 | 8.627E-03 | MGAM; AKT1; PIK3R1 |
hsa00052 | Galactose metabolism_Homo sapiens_hsa00052 | 5.943E-05 | 2.133E-04 | MGAM; AKR1B10; GAA; AKR1B1 |
hsa00983 | Drug metabolism - other enzymes_Homo sapiens_hsa00983 | 4.339E-03 | 8.992E-03 | TK1; CYP3A4; XDH |
hsa04960 | Aldosterone-regulated sodium reabsorption_Homo sapiens_hsa04960 | 3.166E-02 | 4.895E-02 | MAPK1; PIK3R1 |
hsa05216 | Thyroid cancer_Homo sapiens_hsa05216 | 1.141E-03 | 2.867E-03 | MAPK1; PPARG; TP53 |
hsa00350 | Tyrosine metabolism_Homo sapiens_hsa00350 | 2.589E-02 | 4.164E-02 | MAOA; AOX1 |
hsa03410 | Base excision repair_Homo sapiens_hsa03410 | 1.669E-03 | 4.041E-03 | POLB; PARP1; APEX1 |
hsa04320 | Dorso-ventral axis formation_Homo sapiens_hsa04320 | 1.585E-02 | 2.655E-02 | MAPK1; EGFR |
hsa00051 | Fructose and mannose metabolism_Homo sapiens_hsa00051 | 2.189E-02 | 3.577E-02 | AKR1B10; AKR1B1 |
hsa00040 | Pentose and glucuronate interconversions_Homo sapiens_hsa00040 | 2.729E-02 | 4.319E-02 | AKR1B10; AKR1B1 |
hsa00760 | Nicotinate and nicotinamide metabolism_Homo sapiens_hsa00760 | 1.817E-02 | 3.018E-02 | AOX1; CD38 |
hsa04964 | Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | 1.164E-02 | 2.089E-02 | CA2; CA4 |
hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 5.006E-04 | 1.480E-03 | CYP1A2; XDH |
ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
---|---|---|---|
I00-I99: Diseases of the circulatory system | Cardiac arrhythmias | I47-I49 | TBXAS1; ADORA1; ADORA1 |
I00-I99: Diseases of the circulatory system | Cardiac disease | I00-I99 | ADORA1 |
I00-I99: Diseases of the circulatory system | Cardiomyopathy | I42.0 | TTR |
I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | MGAM; HCAR2; KDR |
N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1; PPARG |
I00-I99: Diseases of the circulatory system | Acute ischemic stroke | I61-I63 | HCAR2 |
C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3; ABL1 |
C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TERT; TK1; FLT3; FLT3; AURKB; TP53; TP53 |
C00-D49: Neoplasms | Cancer | C00-C96 | AKT1; MET; TLR2; TK1; MCL1; CSNK2A1; CA1; FLT3; FLT3; CA9; ABL1; MMP2; ACHE; SRC; IGF1R; PTK2; GSK3B; ADORA3; HIF1A; CDK1; MAPK1; MMP9; NFKB1; EGFR; PIM1; PARP1; CD38; BCL2; BCL2; TP53; ESR1; ESR1; KDR; APP |
C00-D49: Neoplasms | Ocular cancer | C69 | APEX1 |
K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE |
S00-T88: Injury, poisoning and certain other consequences of external causes | Vulnerary | S00-T98 | EGFR |
C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | KDR |
C00-D49: Neoplasms | Metastasis | C00-C97 | AXL |
C00-D49: Neoplasms | Metastatic breast cancer | C50 | KDR |
E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | PPARD |
E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic syndrome x | E88.81 | HSD11B1 |
N00-N99: Diseases of the genitourinary system | Menopause symptoms | N95.0 | ESR1; ESR1 |
N00-N99: Diseases of the genitourinary system | Menorrhagia | N92.0 | ESR1 |
C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1; SRC |
C00-D49: Neoplasms | Adrenocortical carcinoma | C74.0 | ESR1 |
A00-B99: Certain infectious and parasitic diseases | Adult varicella zoster virus infection | B02 | TK1 |
NA: NA | Rheumatold arthritis | NA | PTGS1 |
J00-J99: Diseases of the respiratory system | Rhinitis | J00, J30, J31.0 | ALOX5 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | CAMK2B; AKR1B1; PLA2G1B; ESRRA; ALOX5; CASP1; MMP3; MMP1 |
L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | MAOA |
NA: NA | Geographic retinal atrophy | NA | APP |
NA: NA | GIST | NA | FLT3 |
G00-G99: Diseases of the nervous system G00-G99 | Mild to moderate alzheimer disease | G30 | APP |
C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | EGFR; KDR |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; APP |
C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; KDR |
C00-D49: Neoplasms | Advanced prostate cancer | C61 | ESR1 |
C00-D49: Neoplasms | Advanced melanoma | C43 | BCL2 |
C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR |
C00-D49: Neoplasms | Advanced cancers | C00-C96 | EGFR |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | ESR1 |
A00-B99: Certain infectious and parasitic diseases | Sepsis | A40, A41 | ADORA1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ALOX5; ADORA3 |
L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory skin condition | L00-L99 | PARP1 |
A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | ADORA3 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | MAOA; MAOA; FAAH; HCAR2 |
C00-D49: Neoplasms | Malignant adrenal gland cancer | C74.0 | IGF1R |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | MAOA |
C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | MET |
J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3 |
H00-H59: Diseases of the eye and adnexa | Age related macular degeneration | H35.3 | APP |
NA: NA | Upper abdominal bloating | NA | ACHE |
N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE |
C00-D49: Neoplasms | Urethral cancer | NA | EGFR |
J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | MPO; ALOX5; MMP12; MMP12; ADORA2A |
A00-B99: Certain infectious and parasitic diseases | Visceral leishmaniasis | B55.0 | PLA2G1B |
E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | PTPN1; HSD11B1; PPARG; PPARD; PPARD |
C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MET; IGF1R; IGF1R; EGFR; EGFR; AXL; KDR |
K00-K95: Diseases of the digestive system | Non-alcoholic fatty liver disease | K76.0 | PPARG; PPARD |
C00-D49: Neoplasms | Melanoma | C43 | TLR2; TERT; EGFR; PARP1; KDR; KDR |
C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR |
C00-D49: Neoplasms | Malignant tumor | C00-C75, C7A, C7B | EGFR |
NA: NA | Menopausal disorder | NA | ESR1 |
S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | PLA2G1B; ALOX5; ADORA1 |
G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | MAOA; MAPT; ACHE; ACHE; ACHE; GSK3B; PPARG; PPARG; APP |
C00-D49: Neoplasms | AML | NA | FLT3; KDR |
C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR |
G00-G99: Diseases of the nervous system G00-G99 | Spinal muscular atrophy | G00-G99 | SMN1;SMN2 |
C00-D49: Neoplasms | Solid tumours | C00-D48 | AKT1; MET; TLR2; TK1; FLT3; CA9; ABL1; MMP2; SRC; IGF1R; PTK2; AURKB; HIF1A; MAPK1; MMP9; EGFR; TP53; KDR; KDR; KDR |
S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 1 diabetes | E10 | PPARG; PPARD |
C00-D49: Neoplasms | Tumors | C00-D48 | TERT |
A00-B99: Certain infectious and parasitic diseases | Trematode infection | B66.9 | ESR1 |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Convulsions | R56.0 | ADK |
H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
C00-D49: Neoplasms | Head and neck squamous cell carcinoma | C44 | EGFR |
A00-B99: Certain infectious and parasitic diseases | HCV infection | B17.1, B18.2 | MMP3 |
C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | AKR1B1; TERT; EGFR; EGFR; EGFR; TP53; KDR; KDR |
A00-B99: Certain infectious and parasitic diseases | Leishmaniasis | B55.0 | PLA2G1B |
C00-D49: Neoplasms | Leukemia | C90-C95 | AKT1; FLT3; ABL1; BCL2; ESR1 |
C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | PTK2; TP53 |
E00-E89: Endocrine, nutritional and metabolic diseases | Lipid metabolism disorder | E75-E78 | HSD11B1 |
C00-D49: Neoplasms | Liver cancer | C22 | TERT; IGF1R; KDR |
G00-G99: Diseases of the nervous system G00-G99 | Amyotrophic lateral sclerosis | G12.2 | BCL2 |
E00-E89: Endocrine, nutritional and metabolic diseases | Amyloidosis | E85 | APP; TTR |
NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3 |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Anesthesia | R20.0 | FAAH |
S00-T88: Injury, poisoning and certain other consequences of external causes | Myocardial reperfusion injury | T86.4 | AKT1 |
I00-I99: Diseases of the circulatory system | Myocardial infarction | I21, I22 | MMP3; PARP1 |
N00-N99: Diseases of the genitourinary system | Nephritis | N00-N19, N25-N29 | TBXAS1 |
S00-T88: Injury, poisoning and certain other consequences of external causes | Nerve injury | T14.4 | PLA2G1B |
L00-L99: Diseases of the skin and subcutaneous tissue | Pruritus | L29 | PLA2G1B; ALOX5 |
C00-D49: Neoplasms | Prostate cancer | C61 | TLR2; TERT; TK1; FLT3; ABL1; EGFR; BCL2; ESR1 |
N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1 |
C00-D49: Neoplasms | Esophageal cancer | C15 | EGFR |
S00-T88: Injury, poisoning and certain other consequences of external causes | Graft-versus-host disease | T86.0 | TK1 |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Growth failure | R62.8 | IGF1R |
H00-H59: Diseases of the eye and adnexa | Graves' ophthalmopathy | H06.2 | IGF1R |
C00-D49: Neoplasms | Lymphoma | C81-C86 | AKT1; CA9; HIF1A; EGFR; BCL2 |
C00-D49: Neoplasms | Lung cancer | C33-C34 | ABL1; MMP2; EGFR |
C00-D49: Neoplasms | Locally advanced head and neck cancer | C07-C14, C32, C33 | EGFR |
A00-B99: Certain infectious and parasitic diseases | Lymphatic filariasis | B74 | ALOX5 |
K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET; FAAH |
I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR |
I00-I99: Diseases of the circulatory system | Angina pectoris | I20 | TBXAS1 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CAMK2B; MAOA; ACHE; FAAH; CYP3A4 |
I00-I99: Diseases of the circulatory system | Aortic aneurysm | I71 | MMP12 |
G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE |
G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE |
C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3 |
C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | TLR2; KDR |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychotic disorders | F20-F29 | DRD4 |
I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
L00-L99: Diseases of the skin and subcutaneous tissue | Psoriatic disorder | L40 | IGF1R |
J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | PLA2G1B; ESRRA; ADORA2A |
C00-D49: Neoplasms | Hematological malignancies | C81-C86 | SRC; AURKB; CD38; TP53 |
C00-D49: Neoplasms | Glioblastoma | NA | FLT3 |
C00-D49: Neoplasms | Glioblastoma multiforme | C71 | SRC; EGFR; EGFR |
C00-D49: Neoplasms | Gliosarcoma | NA | FLT3 |
H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | AKR1B1; CA1; CA1; ACHE; ADORA3; ADORA2A; ADORA1 |
NA: NA | Gonorrheal vaginitis | NA | ESR1 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | AKR1B1; ABCC1; ABCC1; XDH; PPARG |
J00-J99: Diseases of the respiratory system | Influenza virus | J11.1 | HSD11B1 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2 |
L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory and pruritic manifestations of corticosteroid responsive dermatoses | L20-L30 | PLA2G1B |
L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory and pruritic manifestations of moderate to severe corticosteroid-responsive dermatoses of the scalp | L20-L30 | PLA2G1B |
K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | TBXAS1; PTGS1; PPARG |
C00-D49: Neoplasms | Inflammatory breast cancer | C50 | EGFR |
C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | MPO; PLA2G1B; ALOX5; MMP13; MMP12; PTGS1; FAAH |
C00-D49: Neoplasms | Non-small-cell lung cancer | NA | MMP2; KDR |
E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | ESRRA; FFAR1; HSD11B1 |
H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | CA1; ACHE |
S00-T88: Injury, poisoning and certain other consequences of external causes | Radiation sickness | T66 | TLR2 |
W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Radionuclide imaging | W88 | ADORA2A |
C00-D49: Neoplasms | Recurrent epithelial ovarian or primary peritoneal cancer | C78 | PARP1 |
C00-D49: Neoplasms | Refractory breast cancer | C50 | EGFR |
C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | KDR |
Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Genetic disease | Q00-Q99 | ALPL |
K00-K95: Diseases of the digestive system | Gastrointestinal disease | K00-K93 | ESRRA; EGFR |
I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | SRC; ADORA3 |
N00-N99: Diseases of the genitourinary system | Irregularities | N92.6 | ESR1 |
C00-D49: Neoplasms | Intestinal cancer | NA | ABL1 |
I00-I99: Diseases of the circulatory system | Ischemic stroke | I61-I63 | MMP3 |
G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | MAPT; ACHE |
C00-D49: Neoplasms | Renal cell carcinoma | NA | MMP2; KDR; KDR |
C00-D49: Neoplasms | Renal cancer | C64 | CA9; KDR |
I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
N00-N99: Diseases of the genitourinary system | Renal failure | N17, N18, N19 | ADORA1 |
A00-B99: Certain infectious and parasitic diseases | Infections | A00-B99 | PTPN1 |
A00-B99: Certain infectious and parasitic diseases | Cryptosporidium infection | A07.2 | EGFR |
S00-T88: Injury, poisoning and certain other consequences of external causes | Postoperative inflammation | T81 | PTGS1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | ADORA1; PPARD; ESR1; HCAR2 |
E00-E89: Endocrine, nutritional and metabolic diseases | Hypertriglyceridemia | E78.1, E78.2, E78.3, I47-I49 | ADORA1 |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cachexia | R64 | ESRRA |
C00-D49: Neoplasms | Carcinoma | D00-D09 | ESR1 |
Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Osteopetrosis | Q78.2 | ESR1 |
C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
Z00-Z99: Factors influencing health status and contact with health services | Oral contraceptive | Z30 | ESR1 |
I00-I99: Diseases of the circulatory system | Orthostatic hypotension | I95.1 | ADORA1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Dietary shortage | E40-E46 | ABL1; PTGS1 |
C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
E00-E89: Endocrine, nutritional and metabolic diseases | TTR amyloidosis | E85 | TTR |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | TBXAS1; MGAM; PTPN1; PTPN1; FFAR1; HSD11B1; NFKB1; PPARG; PPARG; PPARD; HCAR2 |
C00-D49: Neoplasms | Breast cancer | C50 | TERT; CYP19A1; FLT3; FLT3; CA9; IGF1R; CDK1; EGFR; EGFR; EGFR; BCL2; ESR1; ESR1; KDR; KDR; KDR |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | AKR1B1; MGAM; PTPN1; FFAR1; HSD11B1; HSD11B1; GSK3B; ADORA1; PPARG |
L00-L99: Diseases of the skin and subcutaneous tissue | Dermatological disease | L00-L99 | ESRRA |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | MAOA |
A00-B99: Certain infectious and parasitic diseases | Dengue fever | A90 | MGAM |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Hyperglycemia | R73.9 | MGAM |
E00-E89: Endocrine, nutritional and metabolic diseases | Hypercholesterolemia | E78 | HSD11B1 |
A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3 |
Z00-Z99: Factors influencing health status and contact with health services | Hormone replacement therapy | Z79.890 | ESR1 |
G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | MAOA; PTGS1; ADORA2A; ADORA1 |
Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | ESR1 |
I00-I99: Diseases of the circulatory system | Coronary disorder diagnosis | I20-I25 | ADORA2A |
C00-D49: Neoplasms | Mesothelioma | C45 | PTK2 |
H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | HSD11B1; CA4; CA4 |
H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | ACHE; CA4; CA2 |
H00-H59: Diseases of the eye and adnexa | Ocular inflammation | H16.229 | TERT; PPARG |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic nephropathy | E11.21 | MMP1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1; PTGS1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1 |
L00-L99: Diseases of the skin and subcutaneous tissue | Diabetic foot ulcer | L88-L89 | ADORA2A; EGFR |
G00-G99: Diseases of the nervous system G00-G99 | Diagnostic imaging | G30, I73.9 | APP |
E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | IGF1R; ESR1; ESR1 |
C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | ESR1 |
I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1 |
H00-H59: Diseases of the eye and adnexa | Corneal ulcers | H16.0 | MMP3 |
I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1 |
J00-J99: Diseases of the respiratory system | Respiratory disease | J00-J99 | ALOX5 |
C00-D49: Neoplasms | Glioma | C71 | ABL1; EGFR; EGFR; KDR; APP |
G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | MMP13; ADK; ACHE; PTGS1; IGF1R; ADORA2A; CDK1; FAAH; ESR1 |
G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | MPO; MAOA; ACHE; ADORA2A; ADORA1 |
A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE |
I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET |
I00-I99: Diseases of the circulatory system | Heart failure | I50 | ADORA1; XDH |
N00-N99: Diseases of the genitourinary system | Vagina disease | N76.0 | ESR1 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Drug abuse | F10-F19 | PPARG |
W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | MET; IGF1R; ADORA3; KDR |
C00-D49: Neoplasms | Hematologic malignancies | C81-C86 | AKT1 |
A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE |
NA: NA | Hepatitis C virus infection | NA | ADORA3 |
NA: NA | Hematopoietic stem cell transplantation | NA | FLT3 |
C00-D49: Neoplasms | Colon cancer | C50 | ALPL; FLT3; EGFR |
NA: NA | Colour dead tissues | NA | PTPN1 |
C00-D49: Neoplasms | Colorectal cancer | C18-C21 | FLT3; PTGS1; IGF1R; MMP9; EGFR; EGFR; TP53; KDR |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Nicotine dependence | F17 | PPARG |
C00-D49: Neoplasms | Osteosarcoma | C40-C41 | SRC; GSK3B |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | SRC; ESR1 |
I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | NR1I2; ALOX5; MMP12; HSD11B1; PPARD; HCAR2 |
J00-J99: Diseases of the respiratory system | Asthma | J45 | TBXAS1; PLA2G1B; ESRRA; ALOX5; ALOX5; MMP12; ADORA2A; ADORA1 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthralgia | M25.5 | ESR1 |
I00-I99: Diseases of the circulatory system | Arteriosclerosis | I70 | PLA2G1B; ADORA2A; HCAR2 |
NA: NA | Dyslipidemia | NA | PPARD |
K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA1; CA2 |
N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | PTGS1; ESR1 |
N00-N99: Diseases of the genitourinary system | Dyspareunia | N94.1 | ESR1 |
NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE |
C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR |
I00-I99: Diseases of the circulatory system | Acute and chronic heart failure | I50 | ADORA1 |
A00-B99: Certain infectious and parasitic diseases | Acquired immune deficiency syndrome | B20 | MGAM |
L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | ESRRA; MMP2; PTGS1; ESR1 |
G00-G99: Diseases of the nervous system G00-G99 | Ataxia telangiectasia | G11.3 | PARP1 |
A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9 |
L00-L99: Diseases of the skin and subcutaneous tissue | Atopic dermatitis | L00-L99 | ALOX5 |
E00-E89: Endocrine, nutritional and metabolic diseases | Atrial fibrillation | E78, I48 | ADORA1; ADORA1 |
N00-N99: Diseases of the genitourinary system | Atrophic vaginitis | N95.2 | ESR1 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Atrophy | M62.571 | ESR1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | TLR2; ADORA1; ESR1 |
G00-G99: Diseases of the nervous system G00-G99 | Encephalopathy | G93.4 | XDH |
NA: NA | Edema | NA | CA2 |
I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | ADORA2A; ADORA1 |
G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | MAOA; CASP1; ADK |
G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ADK; ACHE |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Erectile dysfunction | F52.2, N48.4 | DRD4 |
C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR |
G00-G99: Diseases of the nervous system G00-G99 | Permanent and transient stroke | G45.9, I61-I63 | PARP1 |
S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE |
A00-B99: Certain infectious and parasitic diseases | Infections disease | A00-B99 | MPO |
K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET |
NA: NA | Miosis during ocular surgery | NA | PTGS1 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | MAOA |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | PLA2G1B; ABCC1; ESRRA; ALOX5; MMP1 |
C00-D49: Neoplasms | Bladder cancer | C67 | CYP19A1; EGFR |
E00-E89: Endocrine, nutritional and metabolic diseases | Dyslipidaemias | E78 | PPARD; PPARD |
C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR |
C00-D49: Neoplasms | Ovarian cancer | C56 | TERT; MMP2; EGFR; EGFR; PARP1; KDR; KDR; KDR; KDR |
E00-E89: Endocrine, nutritional and metabolic diseases | Estrogen deficiency | E28.39 | ESR1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | ESR1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricemia | E79.0 | XDH |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricaemia in gout | E79.0, M10 | XDH |
G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAPT; PPARD |
I00-I99: Diseases of the circulatory system | Cerebral amyloid angiopathy | I68.0 | APP |
I00-I99: Diseases of the circulatory system | Cerebrovascular disorders | I60-I69 | PARP1 |
I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | ADORA3; EGFR; PARP1 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | ALOX5; MMP13; MMP3; MMP2; PTGS1 |
G00-G99: Diseases of the nervous system G00-G99 | Motor neurone disease | G12.2 | IGF1R |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Muscle disease | M60-M63 | MGAM |
G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | MPO; ADORA1; ESR1; ESR1 |
C00-D49: Neoplasms | Multiple myeloma | C90 | TERT; SRC; IGF1R; CD38; BCL2 |
C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET |
N00-N99: Diseases of the genitourinary system | Infertility | N97.0 | ESR1 |
C00-D49: Neoplasms | Gastric cancer | C16 | EGFR; EGFR; KDR; KDR |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Fatigue | R53 | ADORA1 |
C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | MAPT; ACHE; ADORA1 |
C00-D49: Neoplasms | CLL | NA | FLT3 |
C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
N00-N99: Diseases of the genitourinary system | Female infertility due to anovulation | N97.0 | ESR1 |
N00-N99: Diseases of the genitourinary system | Female infertility | N97.0 | ESR1; ESR1 |
L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET; CASP1 |
A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | ALOX5; RAB9A |
H00-H59: Diseases of the eye and adnexa | Eye disorders | H00-H59 | ESR1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Female hypogonadism | E23, E28 | ESR1 |
L00-L99: Diseases of the skin and subcutaneous tissue | Contact dermatitis | L23, L24, L25 | PLA2G1B |
C00-D49: Neoplasms | Chronic myelogenous leukaemia | C92.1 | ABL1; ABL1; SRC |
C00-D49: Neoplasms | Chronic lymphocytic leukaemia | C91 | EGFR; BCL2 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | ESRRA; DRD4 |
H00-H59: Diseases of the eye and adnexa | Macular degeneration | H35.3 | APP |
A00-B99: Certain infectious and parasitic diseases | Anthelmintic | B89 | ALPL |
NA: NA | Postmenopausal disorder | NA | ESR1 |
N00-N99: Diseases of the genitourinary system | Post-menopausal vaginal atrophy | N95.2 | ESR1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Pompe's disease | E74.02 | MGAM; GAA |
G00-G99: Diseases of the nervous system G00-G99 | Brain ischaemia | G45.9, I67.8 | PARP1 |
S00-T88: Injury, poisoning and certain other consequences of external causes | Brain injury | S09.90 | APP |
C00-D49: Neoplasms | Brain cancer | C71, D33 | TERT; TK1; SRC; EGFR; EGFR; ESR1 |
I00-I99: Diseases of the circulatory system | Stroke | I61-I63, I80-I82 | MMP9 |
L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | ESRRA; ALOX5; PTGS1 |
K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | PTGS1; MMP9 |
H00-H59: Diseases of the eye and adnexa | Choroidal neovascularisation | H35 | ESRRA |
C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3; ABL1 |
L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | ALOX5; FLT3; EGFR; BCL2 |
S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE |
C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR; KDR |
I00-I99: Diseases of the circulatory system | Thromboembolism | I80-I82 | TBXAS1 |
I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | TBXAS1; ALOX5 |
I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | NPSR1; ESR1; APP |
C00-D49: Neoplasms | Pancreatic cancer | C25 | AKT1; TLR2; TERT; TK1; FLT3; MMP2; EGFR; KDR |